Joint Venture19 Dec 2025, 11:33 am
Pfizer Ltd Enters Exclusive Supply and Marketing Agreement with Cipla Limited for Four Brands
AI Summary
Pfizer Ltd has entered into an exclusive Supply and Marketing Agreement with Cipla Limited for marketing and distribution of four brands, namely Corex Dx, Corex LS, Dolonex, and Neksium for an initial period of 5 years in India. This partnership aims to enhance availability of these key brands for patients across the country, leveraging Pfizer's legacy of breakthroughs, quality, and innovation, and Cipla's extensive distribution reach and network.
Key Highlights
- Pfizer Ltd and Cipla Limited entered into an exclusive Supply and Marketing Agreement for four brands – Corex Dx, Corex LS, Dolonex, and Neksium.
- The agreement is for an initial period of 5 years within the territory of India.
- Cipla will have the sole right to market, distribute and sell these brands in India.
- Pfizer will continue to manufacture, source and supply these medicines to Cipla for India.
- This partnership aims to enhance availability of these key brands for patients across the country.